Literature DB >> 12535829

A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis.

Yuji Okura1, G William Dec, Joshua M Hare, Makoto Kodama, Gerald J Berry, Henry D Tazelaar, Kent R Bailey, Leslie T Cooper.   

Abstract

OBJECTIVES: The goal of this study was to determine the prognostic value of clinical data available at presentation and histology in cardiac sarcoidosis (CS) and idiopathic giant cell myocarditis (IGCM).
BACKGROUND: The prognosis of patients with nonischemic cardiomyopathy is partly dependent on the histologic diagnosis. Survival in IGCM is poor. The prognosis of a histologically related entity, cardiac sarcoidosis (CS), is less well established, and the prognostic value of the distinction between CS and IGCM on endomyocardial biopsy (EMB) is unknown.
METHODS: We identified 115 patients from the Multicenter IGCM Registry with CS (n = 42) and IGCM (n = 73). We compared the clinical data for these two groups using Cox proportional-hazards models to assess the association between histologic diagnosis and survival. In order to determine whether histologic features could reliably differentiate these two entities, two cardiac pathologists semiquantitatively graded the inflammatory infiltrate components and compared the results between groups.
RESULTS: Black race was more frequent in the CS group (31% vs. 4%, p < 0.0001). Syncope and atrioventricular block were also more frequently observed in CS than IGCM (31% vs. 5%, p = 0.0002 and 50% vs. 15%, p < 0.0001, respectively). Left-sided heart failure was more common in IGCM (40% vs. 64%, p = 0.013). In CS patients diagnosed by EMB, the five-year transplant-free survival after diagnosis was 69.8% versus 21.9% for IGCM (p < 0.0001, log-rank test). In multivariate models, presentation with heart failure predicted IGCM, and presentation with heart block or more than nine weeks of symptoms predicted CS. Eosinophils, myocyte damage, and foci of lymphocytic myocarditis were more frequent in IGCM, while granulomas and fibrosis were more frequent in CS.
CONCLUSIONS: Transplant-free survival is better for patients with CS than for IGCM diagnosed by EMB. Presentation with heart failure predicted IGCM, and presentation with heart block or more than nine weeks of symptoms predicted CS.

Entities:  

Mesh:

Year:  2003        PMID: 12535829     DOI: 10.1016/s0735-1097(02)02715-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  61 in total

1.  Multiple forms of sustained monomorphic ventricular tachycardia as common presentation in giant-cell myocarditis.

Authors:  M Granér; J Lommi; M Kupari; A Räisänen-Sokolowski; L Toivonen
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

2.  2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias.

Authors:  Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld
Journal:  J Interv Card Electrophysiol       Date:  2020-10       Impact factor: 1.900

3.  Recurrent cardiac sarcoidosis after heart transplantation.

Authors:  Giacomo Veronese; Manlio Cipriani; Duccio Petrella; Stefano Geniere Nigra; Patrizia Pedrotti; Andrea Garascia; Gabriella Masciocco; Manuela A Bramerio; Karin Klingel; Maria Frigerio; Enrico Ammirati
Journal:  Clin Res Cardiol       Date:  2019-05-09       Impact factor: 5.460

4.  Giant cell myocarditis.

Authors:  Naga Vaishnavi Gadela; Anand Muthu Krishnan; Osama Mukarram; Nitya Sthalekar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-01-22

Review 5.  Cardiac Autoimmunity: Myocarditis.

Authors:  William Bracamonte-Baran; Daniela Čiháková
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

6.  Search for key manifestations to predict inflammation on cardiac PET in suspected cardiac sarcoidosis population.

Authors:  Vasileios Kouranos; Kshama Wechalekar
Journal:  J Nucl Cardiol       Date:  2017-06-27       Impact factor: 5.952

7.  Risk assessment of patients with clinical manifestations of cardiac sarcoidosis with positron emission tomography and magnetic resonance imaging.

Authors:  Paco E Bravo; Ganesh Raghu; David G Rosenthal; Shana Elman; Bradley J Petek; Laurie A Soine; Jeffrey H Maki; Kelley R Branch; Sofia C Masri; Kristen K Patton; James H Caldwell; Eric V Krieger
Journal:  Int J Cardiol       Date:  2017-03-10       Impact factor: 4.164

Review 8.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

9.  Right ventricular sarcoidosis: is it time for updated diagnostic criteria?

Authors:  Kairav Vakil; Elina Minami; Daniel P Fishbein
Journal:  Tex Heart Inst J       Date:  2014-04-01

Review 10.  Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?

Authors:  M Pauschinger; M Noutsias; D Lassner; H-P Schultheiss; U Kuehl
Journal:  Clin Res Cardiol       Date:  2006-08-16       Impact factor: 5.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.